Compare Norfolk Southern Corporation (NSC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Sana Biotechnology Inc — how do they compare? Norfolk Southern Corporation trades at $317.62 (market cap $71.20B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Norfolk Southern Corporation is far larger — about 85.1× Sana Biotechnology Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Sana Biotechnology Inc for 23 Days on average.
| NSC | SANA | |
|---|---|---|
Market Cap | $71.20B | $836.71M |
Volume | 555,248 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $352.98 | $5.92 |
52-Week Low | $278.19 | $2.68 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $86.75B | $749.96M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $317.79, up 1.47% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 22, 2026. Fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though revenue growth is modest. The proposed merger with Union Pacific is a key development, gaining regulatory and customer support.
The outlook is positive, supported by earnings momentum and merger potential, offering upside to the $361.86 consensus price target. Risks include merger approval uncertainty, fuel cost pressures noted in September 2026, and a high P/E ratio of 27.05. Institutional interest remains strong, with recent investments from firms like Bank of America.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
